Regenacy

Regenacy Pharmaceuticals is a clinical-stage biopharmaceutical company that restores biological function through protein acetylation for the treatment of diabetes and other peripheral neuropathies as well as other chronic diseases. Compared with non-selective HDAC inhibitors, the company's selective inhibition technology offers superior safety and potentially enhanced efficacy. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathy, and also possesses a combination of selective HDAC 1 and 2 inhibitors, which have the potential to treat major blood disorders such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological diseases.